SNSS - Sunesis Pharmaceuticals, Inc.
| Previous Close | 0.8450 |
| Open | 0.8400 |
| Bid | 0.8200 x 3100 |
| Ask | 0.8392 x 1100 |
| Day's Range | 0.8367 - 0.8450 |
| 52 Week Range | 0.2000 - 2.2600 |
| Volume | 6,333 |
| Avg. Volume | 1,039,273 |
| Market Cap | 60.684M |
| Beta (3Y Monthly) | 4.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6030 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.17 |
- Thomson Reuters StreetEvents
Edited Transcript of SNSS earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call
- Zacks
Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire
Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019. Loss from.
- GlobeNewswire
Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., July 31, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7th, 2019 at.
- Simply Wall St.
How Many Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Shares Do Institutions Own?
A look at the shareholders of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) can tell us which group is most powerful...
- Benzinga
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
- GlobeNewswire
Sunesis Announces Pricing of $25 Million Offering of Securities
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock (“Series F Stock”). The public offering price of each share of common stock is $0.60 and the public offering price of each share of Series F Stock, convertible into 1,000 shares of common stock, is $600. Sunesis expects to receive combined gross proceeds of approximately $25 million from these offerings, before deducting the underwriting discounts and other estimated offering expenses. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 5,000,050 shares of common stock to cover over-allotments, if any.
- GlobeNewswire
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President, Research & Development and the promotion of Parvinder (Par) S. Hyare from Vice President, Global Oncology Operations to Senior Vice President, Commercial. Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, and an A.B. in Chemistry from Bryn Mawr College.
- Zacks
Options Traders Expect Huge Moves in Sunesis (SNSS) Stock
Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
- Benzinga
The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
- Benzinga
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
- Thomson Reuters StreetEvents
Edited Transcript of SNSS earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call
- Associated Press
Sunesis: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 10 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by ...
- GlobeNewswire
Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 --.
- Zacks
What's in the Cards for Sunesis (SNSS) This Earnings Season?
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
- GlobeNewswire
Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Wednesday, May 8th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
- GlobeNewswire
Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank. The new agreement allows the company to retire its existing loan and defer any principal repayment on the new loan for more than 18 months. The new facility includes interest-only payments through 2020, with principal repayment over 24 months beginning in 2021, as well as a lower interest rate than the previous loan.
- ACCESSWIRE
Four Healthcare Stocks Heating Up on Thursday
This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.
- GlobeNewswire
Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.
- Zacks
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
- Zacks
5 Cancer-Fighting Stocks to Boost Portfolio Gains
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
- ACCESSWIRE
Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)
LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first ...
- Zacks
Will Sunesis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.
